

AGENDA

Friday, February 7th, 2020.

14:00 Registration, Welcome cocktail reception and Exhibits

15:00 Welcome and Introductions

General Session 1

15:10 – 16:45

Moderator: Snježana Tomić

15:10 Snježana Ramić: "Microscaled Proteogenomics Methods for Precision Oncology"

15:25 Robert Likić: "Antibody-drug conjugates in cancer: principles for synthesis and preclinical development"

15:40 Snježana Tomić: "Evaluation of Pathologic Response after Neoadjuvant Chemotherapy"

15:55 Paula Podolski: "Neoadjuvant systemic therapy (NST): Tailoring response by subtype"

16:10 Robert Šeparović: "KEYNOTE-522. Phase 3 Study of Neoadjuvant Pembrolizumab+Chemotherapy versus Placebo+Chemotherapy, Followed by adjuvant Pembrolizumab versus Placebo for Early Triple Negative Breast Cancer: Pathologic Complete response in Key Subgroups and by Treatment exposure and Residual Cancer Burden"

16:25 Maja Sirotković Skerlev: " Detection of ctDNA and CTCs after neoadjuvant chemotherapy is associated with disease recurrence in triple-negative breast cancer: preplanned analyses from trial BRE 12-158"

16:40 Q& A

16: 45 Coffee break and Exhibits

Local therapy session 1

17:05 – 17:40

Moderator: Rado Žic

17:05 Rado Žic: De-escalation in Breast Surgery results of the "MICRA Trial"

17:20 Janez Žgajnar (SLO): "Regional Management of the Axilla prior to Systemic Therapy"

17:35 Q & A

Local therapy session 2 17:40 – 18:30

Moderator: Martina Bašić Koretić

- 17:40 Marijana Jazvić: “Guiding Decisions to Omit Radiotherapy after Breast-Conserving Surgery for DCIS. Can Genomic Biomarkers Help?”
- 17:55 Katarina Antunac: “Guiding Selection of RT Approach After Lumpectomy”
- 18:10 Josipa Flam: “Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer. 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial”
- 18:25 Q & A

Saturday, February 8rd , 2020.

General session 2 8:30 – 10:00

Moderator: Eduard Vrdoljak

- 8:30 Branka Petrić Miše: ”Interim Overall Survival Analysis of APHINITY. A randomised multi-center, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer”
- 8:45 Stjepko Pleština: “TBCRC 033: A Randomized Phase 2 Trial of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel with Trastuzumab for Stage 1 HER2+ Breast Cancer (ATEMPT)”.
- 9:00 Eduard Vrdoljak: “Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Previously Treated HER2+ Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)”
- 9:15 Anuška Budisavljević : “Phase 3 SOPHIA study of Margetuximab+chemotherapy vs Trastuzumab+ Chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis”.
- 9:30 Josipa Jović Zlatović: “Trastuzumab Deruxtecan (DS-8201) in HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: DESTINY-Breast01 Study”
- 9:45 Zlatko Marušić : “Origins and Clinical Implications of HER2 Heterogeneity”
- 10: 00 Q & A

Debate 10:05-10:35

“Mastectomy should not be offered to patients who are breast conservation candidates when modern radiotherapy is available” (oncologist vs. surgeon)

- 10:05 Martina Bašić Koretić: “Breast conservation (lumpectomy + RT) is the ‘treatment of choice’ for most patients with breast cancer”
- 10:20 Anto Dujmović : “Mastectomy should be offered to patients who are breast conservation candidates when modern radiotherapy is available”
- 10:35 Coffee break and Exhibits

Prevention, screening and imaging section 11:00 – 12:00

Moderator: Maja Prutki

- 11:00 Mario Škerija: “Long-term Results of the International Breast cancer Intervention Study II (IBIS-II), using Anastrozole”
- 11:15 Zoran Brnić: First Cost and Effects in FaMRIs: a RCT comparing MRI with mammography in screening for Familial risk
- 11:30 Maja Prutki: “Targeted approach to Breast Cancer Surveillance in High Risk Woman: Update of the Newest Technologies & How to use them”
- 11:45 Boris Brkljačić: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: results of a prospective multicenter trial
- 12:00 Q & A
- 13:30 Lunch and Exhibits

General session 3 14:30 – 16:10

Moderator: Stjepko Pleština

- 14:30 Simona Borštnar (SLO): "Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X"

- 14:45 Maja Božić: "Improvements since 2000. in the outcome of ER+ disease after 5 years of adjuvant endocrine therapy: Analyses of 86,000 women in 110 trials"
- 15:00 Natalija Dedić Plavetić: "SOLTI-1402 CORALLEEN phase II trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: an open-label, multicenter, two-arm, randomized study"
- 15:15 Ingrid Belac Lovasić: "Future Directions in Endocrine Therapy for Advanced HR+/HER2- Breast Cancer".
- 15:30 Željko Vojnović: "TBCRC 031: A randomized phase II study of preoperative cisplatin (CDDP) vs doxorubicin & cyclophosphamide (AC) in germline *BRCA* mutation carriers with newly diagnosed breast cancer (the INFORM trial)
- 15:45 Ilijan Tomaš: "Effects of capecitabine as part of neo-/adjuvant chemotherapy A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients "
- 16:00 Summary and Closing Remarks